Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle

Muscle and Nerve

Volumn 27, Issue 5, 2003, Pages 624-627

  Dunant, Patrick ^a   Walter, Maggie C ^a   Karpati, George ^b   Lochmüller, Hanns ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Aminoglycoside antibiotics; Duchenne Becker muscular dystrophy; Dystrophin; Gentamicin; mdx; Stop codon

Indexed keywords

AMINOGLYCOSIDE; DYSTROPHIN; GENTAMICIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; IN VIVO STUDY; MALE; MOUSE; MUSCLE FORCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TIBIALIS ANTERIOR MUSCLE; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; C57BL MOUSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY; TREATMENT FAILURE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; DYSTROPHIN; GENE EXPRESSION REGULATION; GENTAMICINS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; TREATMENT FAILURE;

EID: 0037408464     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10341     Document Type: Article

References (21)

1. Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet 2000;9:2507-2515.
2. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104:375-381.
3. Bönnemann CG, Passos-Bueno R, McNally EM, Vainzoff M, de Sá Moreira E, Marie SK, Pavanello RCM, Noguchi S, Ozawa E, Zatz M, Kunkel LM. Genomic screening for β-sarcoglycan mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E). Hum Mol Genet 1996;5:1953-1961.
4. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-1692.
5. Dolinsky LCB, Moura-Neto RS, Falcao-Conceicao. DGGE analysis as a tool to identify point mutations, de novo mutations and carriers of the dystrophin gene. Neuromuscul Disord 2002;12:845-848.
6. Dubowitz V. Special Centennial Workshop - 101st ENMC International Workshop: Therapeutic Possibilities in Duchenne Muscular Dystrophy, 30th November - 2nd December 2001, Naarden, The Netherlands. Neuromuscul Disord 2002;12:421-431.
7. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000;9:1787-1793.
8. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-469.
9. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000;48:164-169.
10. Karpati G, Lochmüller H. When running a stop sign may be a good thing. Ann Neurol 2001;49:693-694.
11. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-Liduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001;10:291-299.
12. Loveless MO, Kohlhepp SJ, Gilbert DN. The influence of aminoglycoside antibiotics on the in vitro function of rat liver ribosomes. J Lab Clin Med 1984;103:294-303.
13. Lynch SR, Puglisi JD. Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J Mol Biol 2001;306:1037-1058.
14. Mankin AS, Liebman SW. Baby, don't stop! Nat Genet 1999; 23:8-10.
15. Mendell JR, Buzin CH, Feng J, Yan J, Serrano C, Sangani DS, Wall C, Prior TW, Sommer SS. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 2001;57:645-650.
16. Peri V, Ajdukovic B, Holland P, Tuana BS. Dystrophin predominantly localizes to the transverse tubule/Z-line regions of single ventricular myocytes and exhibits distinct associations with the membrane. Mol Cell Biochem 1994;130:57-65.
17. Serrano C, Wall C, Moore SA, King W, Barresi R, Campbell KP, Noticewala P, Brown RH, Nagarja HN, Mendell JR. Gentamicin treatment for muscular dystrophy patients with stop codon mutations. Neurology 2001;56(Suppl):A79.
18. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-711.
19. Walter MC, Lochmüller H. Novel approaches to treat muscular dystrophies. Expert Opin Invest Drugs 2001;10:695-707.
20. Yang L, Lochmüller H, Luo J, Massie B, Nalbantoglu J, Karpati G, Petrof BJ. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Ther 1998;5:369-379.
21. Yoshizawa S, Fourmy D, Puglisi JD. Structural origins of gentamicin antibiotic action. EMBO J 1998;17:6437-6448.